Research programme: integrin inhibitors - Indalo Therapeutics

Drug Profile

Research programme: integrin inhibitors - Indalo Therapeutics

Alternative Names: CWHM-12

Latest Information Update: 20 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Saint Louis University
  • Developer Indalo Therapeutics; Saint Louis University
  • Class Small molecules
  • Mechanism of Action Integrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fibrosis

Most Recent Events

  • 17 Oct 2016 Antegrin plans clinical trials in Fibrosis in 2019
  • 17 Oct 2016 Cascadia Therapeutics has merged with Antegrin Therapeutics to form Indalo Therapeutics
  • 22 Mar 2016 Antegrin in-licenses Integrin inhibitors from Saint Louis University before March 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top